nav-left cat-right
cat-right

J. Craig Venter’s Human Longevity is about ...

In a media briefing hosted in San Diego, Calif., J. Craig Venter—best known as the man who raced against the international Human Genome Project to assemble the first whole human genome sequence in the early 2000s—today announced the opening of a new commercial company, Human Longevity, Inc., to apply genetic sequencing on a massive scale to some of the most intractable questions about human health and aging. “Thirteen...

Stem cell therapy improves Parkinson’s sympt...

International Stem Cell Corp. is inching closer to bringing its stem cell therapy for Parkinson’s to the FDA in hopes of eventually reversing the disease’s symptoms in people. In collaboration with researchers at the Yale University Medical School, International Stem Cell Corp. has released positive data from a key preclinical trial that sets the Carlsbad, CA-based company on course for filing an investigational...

Key indicator of heart diseases

A team that includes Dartmouth College researchers has discovered a new way to detect cardiolipin, a key indicator of heart diseases and some genetic disorders. The results, which appear in the journal Analytical Chemistry, may eventually help to diagnose these conditions earlier on and to provide real-time monitoring of cardiolipin levels. Cardiolipin is a unique lipid of mitochondria, the cell structures that generate...

Mechanism in Alzheimer’s-related memory loss

Cleveland Clinic researchers have identified a protein in the brain that plays a critical role in the memory loss seen in Alzheimer’s patients, according to a study to be published in the journal Nature Neuroscience and posted online. The protein – Neuroligin-1 (NLGN1) – is known to be involved in memory formation; this is the first time it’s been linked to amyloid-associated memory loss. In Alzheimer’s...

Biogen Idec, Proteostasis forge neurodegenerative ...

CAMBRIDGE, Mass.—Alzheimer’s disease, and some of its neurodegenerative cousins, came under fire from a new direction as Proteostasis Therapeutics Inc. this month brought in the R&D and clinical firepower of fellow Cambridge-based company Biogen Idec. in a worldwide collaboration agreement. The deal combines Proteostasis Therapeutics’ proprietary scientific platform and preclinical work on protein degradation with...

Billionaire backs new program for a pioneering Alz...

German billionaire Dietmar Hopp is adding to his multimillion-dollar wager on AC Immune, the Swiss biotech that is playing a key role in some high-profile Alzheimer’s programs. Hopp has been the primary investor behind the company, and today he joined in a $22 million D round designed to fund a new therapeutic vaccine program aimed at the memory-wasting disease. AC Immune isn’t built like most biotechs. CEO Andrea...
Page 3 of 812345...Last »